Extrusion-spheronisation of highly loaded 5-ASA multiparticulate dosage forms

被引:31
作者
Di Pretoro, G. [2 ]
Zema, L. [2 ]
Gazzaniga, A. [2 ]
Rough, S. L. [1 ]
Wilson, D. I. [1 ]
机构
[1] Dept Chem Engn & Biotechnol, Cambridge CB2 3RA, England
[2] Dipartimento Sci Farmaceut P Pratesi, I-20133 Milan, Italy
关键词
5-Aminosalicylic acid; Ram extrusion; Liquid phase migration; Microcrystalline cellulose; Granulation; LIQUID-PHASE MIGRATION; SPHERONIZATION; EXTRUSION/SPHERONIZATION; PELLETS; WATER; ACID; DRUG;
D O I
10.1016/j.ijpharm.2010.10.003
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of the current work was to develop an extrusion-spheronisation (E-S) route to manufacture pellets with a high loading (>= 90 wt%) of 5-aminosalicylic acid (5-ASA). Ram extrusion studies, supported by centrifuge testing, were employed to investigate the effect of the chemical (acidity) and physical (particle size and shape) characteristics of 5-ASA on the ability of microcrystalline cellulose (MCC)-based pastes to retain water when subjected to pressure. Liquid phase migration (LPM) within the paste during the extrusion, and hence variation in water content of extrudates and reproducibility of the final E-S product, was generally observed. The extent of LPM was found to be related to both the drug loading and its physical properties, most notably the particle shape (needle-like). A reduction in particle size, combined with a change in the shape of the 5-ASA particles, allowed LPM to be reduced considerably or eliminated. The performance of colloidal grades of MCC (Avicel RC591 and CL611) as alternative extrusion aids to the standard Avicel PH101 was also investigated: these proved to be superior aids for the highly loaded 5-ASA pastes as their greater water retention capacity mitigated LPM. Combining these results yielded a route for manufacturing pellets with 5-ASA loading >= 90 wt%. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:153 / 164
页数:12
相关论文
共 30 条
[1]  
ALLGAYER H, 1985, ARZNEIMITTEL-FORSCH, V35-2, P1457
[2]  
[Anonymous], J RHEOL
[3]  
[Anonymous], EUR J PHARM SCI
[4]  
[Anonymous], INT J PHARM
[5]   THE INFLUENCE OF MOISTURE-CONTENT ON THE PREPARATION OF SPHERICAL GRANULES OF BARIUM-SULFATE AND MICROCRYSTALLINE CELLULOSE [J].
BAINS, D ;
BOUTELL, SL ;
NEWTON, JM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1991, 69 (03) :233-237
[6]   CONTROLLED-RELEASE MULTIPLE-UNITS AND SINGLE-UNIT DOSES - LITERATURE-REVIEW [J].
BECHGAARD, H ;
NIELSEN, GH .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1978, 4 (01) :53-67
[7]   The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis [J].
Buckland, A. ;
Bodger, K. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2008, 28 (11-12) :1287-1296
[8]   Nonadherence in inflammatory bowel disease:: Results of factor analysis [J].
Cerveny, Petr ;
Bortlik, Martin ;
Kubena, Ales ;
Vlcek, Jiri ;
Lakatos, Peter Laszlo ;
Lukas, Milan .
INFLAMMATORY BOWEL DISEASES, 2007, 13 (10) :1244-1249
[9]   Sustained Delivery of Intact Drug to the Colon: Mesalamine Formulation and Temporal Gastrointestinal Transit Analysis [J].
Chuong, Monica C. ;
Christensen, J. Mark ;
Ayres, James W. .
PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2009, 14 (01) :116-125
[10]   Review article: evolutionary advances in the delivery of aminosalicylates for the treatment of ulcerative colitis [J].
Cohen, R. D. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 24 (03) :465-474